Skip to main content

Development of small molecule OGG1 Inhibitor and proof of concept in bleomycin-induced disease model of Inflammation and pulmonary Fibrosis

Project description

A molecular inhibitor against pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive condition characterised by pathological inflammation and scarring in the lungs. The causes of IPF are unknown, and there is no cure, with most patients surviving approximately three years after diagnosis. Scientists of the EU-funded DOIIF project had previously developed an inhibitor of the OGG1 enzyme, which is implicated in DNA repair during oxidative stress. Since inhibition of OGG1 seems to reduce inflammation and fibrosis and slow down IPF, researchers aim to take a lead compound through preclinical development and clinical phase 1/2a for further commercialisation.

Host institution

KAROLINSKA INSTITUTET
Net EU contribution
€ 150 000,00
Address
Nobels Vag 5
17177 Stockholm
Sweden

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
No data

Beneficiaries (1)

KAROLINSKA INSTITUTET
Sweden
Net EU contribution
€ 150 000,00
Address
Nobels Vag 5
17177 Stockholm

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
No data